Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection

Recruiting N/A Interventional Study
Potassium-Competitive Acid Blocker Proton Pump Inhibitor Bismuth Based Quadruple Therapy Treatment Helicobacter Pylori Infection
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
320 (estimated)
Sponsor
Tanta University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This study aims to compare the eradication rate, safety, and patient adherence between potassium-competitive acid blockers (P-CABs) and proton pump inhibitor-based bismuth quadruple therapy in patients with Helicobacter pylori infection.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Adults aged ≥18 years. * Both sexes. * Confirmed Helicobacter pylori infection by stool antigen (3rd-gen ELISA) or urea breath test (UBT). * No prior eradication therapy. Exclusion Criteria: * Prior Helicobacter pylori treatment. * Use of antibiotics, proton pump inhibitor, …
Contacts

Mohamed G Flefel, MD

00201009156988

mohamed.galal@med.tanta.edu.eg

CONTACT